|1.||Oosterwijk, Egbert: 5 articles (01/2013 - 09/2003)|
|2.||Boerman, Otto C: 4 articles (01/2013 - 09/2003)|
|3.||Oyen, Wim J G: 3 articles (03/2005 - 09/2003)|
|4.||Corstens, Frans H M: 3 articles (03/2005 - 09/2003)|
|5.||Mulders, Peter F A: 2 articles (01/2013 - 09/2003)|
|6.||Brouwers, Adrienne H: 2 articles (02/2004 - 09/2003)|
|7.||Boettger, Volker: 1 article (12/2014)|
|8.||Ditte, Peter: 1 article (12/2014)|
|9.||Pastorekova, Silvia: 1 article (12/2014)|
|10.||Csaderova, Lucia: 1 article (12/2014)|
|1.||Renal Cell Carcinoma (Grawitz Tumor)
03/08/2004 - "A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients."
11/01/1998 - "In previous studies, highly heterogeneous uptake of 131I-labelled chimeric monoclonal antibody G250 ([131I]cG250) in primary renal cell carcinomas has been observed (intratumoral differences > factor 100). "
04/01/1993 - "Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250."
05/10/2004 - "Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation."
09/01/2003 - "Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison."
08/01/2004 - "Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies."
04/01/1999 - "The constant 131I/125I ratios, observed in all tumor samples investigated, indicate that the tumor parameters governing cG250 mAb uptake were not altered significantly within the time period studied. "
11/01/1998 - "On the basis of external imaging, 131I-labeled mouse monoclonal antibody G250 showed excellent localization to all tumors that were > or =2 cm. Seventeen of 33 patients had stable disease, with tumor shrinkage observed in two patients. "
02/01/2003 - "Wilex AG, in collaboration with the Ludwig Institute for Cancer Research, is developing WX-G250, a kappa light chain chimeric antibody derived from the variable region of the mouse monoclonal antibody G250, for the potential treatment of biliary cancer and renal cell carcinoma (RCC). "
03/01/1999 - "Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250."
|3.||Kidney Neoplasms (Kidney Cancer)
|2.||Immunoglobulin G (IgG)
|6.||Carbonic Anhydrases (Carbonic Anhydrase)
|7.||Antibody Binding Sites
|8.||Surface Antigens (Surface Antigen)
|10.||glucuronyl glucosamine glycan sulfate (Vessel)
|2.||Heterologous Transplantation (Xenotransplantation)